Category: 106685-40-9

In 2019,Journal of Research in Medical Sciences included an article by Mokhtari, Fatemeh; Shajari, Atefeh; Iraji, Fariba; Faghihi, Gita; Siadat, Amir Hossein; Sadeghian, Giti; Adibi, Neda. Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《The effectiveness of adapalene 0.1% with intense pulsed light versus benzoyl peroxide 5% with intense pulsed light in the treatment of acne vulgaris: A comparative study》. The information in the text is summarized as follows:

Background: Acne vulgaris (AV) is one of the most common skin diseases with major psychol. impacts. Hence, selecting the best treatment modality is so important; there are different ways to treat AV such as topical and systemic agents, laser, and also photodynamic therapy. In this study, we tried to assess the difference between the efficacy of combination therapy with intense pulsed light (IPL) and benzoyl peroxide (BPO) in comparison with IPL and adapalene (AD) in the treatment of the mild to moderate AV. Materials and Methods: Thirty Iranian females in reproductive age with mild to moderate acne were enrolled in this study. The left and right side of the patients were randomized to receive either AD 0.1% or BPO 5% every other day plus three sessions of monthly apart IPL in the treatment of AV. Different parameters of AV such as acne severity index (ASI), total acne lesions counting (TLC), and Acne Global Severity Scale (AGSS) were measured before, during, and after the treatments. Results: There was a significant difference regarding AGSS, TLC, and ASI before and after treatment with AD plus IPL (P < 0.001). Furthermore, there was a significant difference regarding AGSS, TLC, and ASI before and after treatment with BP plus IPL (P < 0.001). However, no significant difference regarding AGSS, TLC, and ASI were observed between the 2 groups after treatment (P > 0.05). No significant side effects were observed in both groups. Conclusion: Our study shows that there was not any significant difference between combining IPL with either AD or BPO so we can use either one of these combinations to achieve similar efficacy. In the experiment, the researchers used 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

《Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.》 was written by Stein Gold, Linda; Baldwin, Hilary; Kircik, Leon H; Weiss, Jonathan S; Pariser, David M; Callender, Valerie; Lain, Edward; Gold, Michael; Beer, Kenneth; Draelos, Zoe; Sadick, Neil; Pillai, Radhakrishnan; Bhatt, Varsha; Tanghetti, Emil A. Recommanded Product: 106685-40-9 And the article was included in American journal of clinical dermatology in 2021. The article conveys some information:

BACKGROUND: A three-pronged approach to acne treatment-combining an antibiotic, antibacterial, and retinoid-could provide greater efficacy and tolerability than single or dyad treatments, while potentially improving patient compliance and reducing antibiotic resistance. OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicenter, randomized, 12-week study, eligible participants aged ≥ 9 years with moderate-to-severe acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels: BPO/adapalene; clindamycin phosphate/BPO; or clindamycin phosphate/adapalene. Coprimary endpoints were treatment success at week 12 (participants achieving a ≥ 2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion counts to week 12. Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed. RESULTS: A total of 741 participants were enrolled. At week 12, 52.5% of participants achieved treatment success with IDP-126 vs vehicle (8.1%) and dyads (range 27.8-30.5%; P ≤ 0.001, all). IDP-126 also provided significantly greater absolute reductions in inflammatory (29.9) and noninflammatory (35.5) lesions compared with vehicle or dyads (range inflammatory, 19.6-26.8; noninflammatory, 21.8-30.0; P < 0.05, all), corresponding to > 70% reductions with IDP-126. IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity. CONCLUSIONS: Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017).6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Recommanded Product: 106685-40-9) was used in this study.

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Recommanded Product: 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Journal of Histochemistry and Cytochemistry included an article by Hejboel, Eva K.; Hajjaj, Mohammad A.; Nielsen, Ole; Schroeder, Henrik D.. Synthetic Route of C28H28O3. The article was titled 《Marker Expression of Interstitial Cells in Human Skeletal Muscle: An Immunohistochemical Study》. The information in the text is summarized as follows:

There is a growing recognition that myogenic stem cells are influenced by their microenvironment during regeneration. Several interstitial cell types have been described as supportive for myoblasts. In this role, both the pericyte as a possible progenitor for mesenchymal stem cells, and interstitial cells in the endomysium have been discussed. We have applied immunohistochem. on normal and pathol. human skeletal muscle using markers for pericytes, or progenitor cells and found a cell type co-expressing CD10, CD34, CD271, and platelet-derived growth factor receptor a omnipresent in the endomysium. The marker profile of these cells changed dynamically in response to muscle damage and atrophy, and they proliferated in response to damage. The cytol. and expression profile of the CD10+ cells indicated a capacity to participate in myogenesis. Both morphol. and indicated function of these cells matched properties of several previously described interstitial cell types. Our study suggests a limited number of cell types that could embrace many of these described cell types. Our study indicate that the CD10+, CD34+, CD271+, and platelet-derived growth factor receptor a+ cells could have a supportive role in human muscle regeneration, and thus the mechanisms by which they exert their influence could be implemented in stem cell therapy. In the experiment, the researchers used many compounds, for example, 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Synthetic Route of C28H28O3)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Synthetic Route of C28H28O3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Swathi, G.; Deepthi, G.; Visakh, Deepthi; Prathyusha, J.; Fatima, Nafees; lakshmi, M. Sai published their research in Indo American Journal of Pharmaceutical Sciences in 2021. The article was titled 《Development and validation for estimation of clindamycin, adapalene and sofosbuvir in bulk and pharmaceutical dosage forms by rp-hplc method》.HPLC of Formula: 106685-40-9 The article contains the following contents:

A simple, accurate, rapid and precise isocratic stability indicating reversed-phase high-performance liquid chromatog. method has been developed and validated for simultaneous determination of Clindamycin and Adapalene in tablets. The chromatog. separation was carried out on C18 BDS Hypersil (150 × 4.6mm, 5μ) with a mixture ofmixed phosphate buffer : acetonitrile (55:45%volume/volume) as a mobile phase at a flow rate of 1.0mL/min. UV detection was performed at 230nm. The retention times were2.84 and 3.999min for Clindamycin and Adapalene resp. Calibration plots were linear (r2 = 0.999) over the concentration range of 25-150μg/mL for Clindamycin and 2.5-15μg/mL for Adapalene. The method was validated for accuracy, precision, specificity, linearity and sensitivity. The proposed method was successfully used for quant. anal. of tablets. No interference from any component of pharmaceutical dosage form was observed Validation studies revealed that method is specific, rapid, reliable, and reproducible. The high recovery and low relative standard deviation confirm the suitability of the method for routine determination of Clindamycin and Adapalene in bulk and tablet dosage form. Sofosbuvir is used primarily to treat hepatitis C and viral hemorrhagic fevers. It is possible to select a sofosbuvir resistant mutant of HCV that can replicate to levels similar to wild type virus grown without sofosbuvir. Anal. of the mutations responsible for the sofosbuvir resistance may aid in understanding the mechanism of action of sofosbuvir. The results came from multiple reactions, including the reaction of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9HPLC of Formula: 106685-40-9)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.HPLC of Formula: 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

《Validated stability-indicating HPTLC method for the estimation of adapalene in drugs and the LC-MS identification of its degradation products》 was published in Journal of Planar Chromatography–Modern TLC in 2020. These research results belong to Thummar, Kashyap; Tilva, Kevin; Dudhatra, Bhumika; Mardia, Rajnikant; Sheth, Navin. Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid The article mentions the following:

A highly sensitive, simple, accurate, and precise high-performance thin-layer chromatog. (HPTLC) method was developed and validated for the quant. determination of adapalene in the presence of its degradation products. The method employed precoated silica gel G 60 F254 on aluminum sheets using an appropriate solvent system which gives a compact spot of adapalene at RF value 0.58. The densitometric measurement of adapalene bands was carried out at 317 nm in fluorescence mode. The method was validated over a range of 10-100 ng/band. The linear regression data for the calibration plot showed a good relationship with high correlation coefficients The performance of the method was validated for precision, accuracy, and robustness. The limits of detection and quantification were 1.52 and 4.61 ng/band, resp. Adapalene was subjected to the ICH-prescribed acidic, alk., oxidative, photolytic, and thermal stress conditions, and it undergoes degradation with well-resolved degradation products. These degradation products were further analyzed by mass spectrometry to elucidate the structure of degradation products and proposed the prediction of the degradation pathway. The experimental process involved the reaction of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

The author of 《Diabetes impairs the angiogenic capacity of human adipose-derived stem cells by reducing the CD271+ subpopulation in adipose tissue》 were Inoue, Oto; Usui, Soichiro; Takashima, Shin-ichiro; Nomura, Ayano; Yamaguchi, Kosei; Takeda, Yusuke; Goten, Chiaki; Hamaoka, Takuto; Ootsuji, Hiroshi; Murai, Hisayoshi; Kaneko, Shuichi; Takamura, Masayuki. And the article was published in Biochemical and Biophysical Research Communications in 2019. Category: ethers-buliding-blocks The author mentioned the following in the article:

Type 2 diabetes mellitus is an important risk factor for cardiovascular diseases (CVDs). Therapeutic angiogenesis using adipose-derived stem cells (ADSCs) is attractive for CVD therapy. However, although it would be critical for ADSC application on CVD therapy, whether and how diabetes impairs human ADSC therapeutic potential is still uncertain. In this study, we aimed to investigate the impact of diabetes on the angiogenic potential of ADSCs in patients with CVDs, with special focus on stemness-related genes and cellular alteration of ADSCs. This paper established cultured ADSCs from diabetic (DM-ADSCs) and non-diabetic patients (nonDM-ADSCs) with CVDs. DM-ADSCs demonstrated limited proliferative capacity and reduced paracrine capacity of VEGF, with lower expression of the stemness gene SOX2. Angiogenic capacity and ADSC engraftment were assessed using xenograft experiments in a hindlimb ischemia model of athymic nude mice. Consistent with the results of in vitro assays, DM-ADSCs did not rescue limb ischemia. In contrast, nonDM-ADSCs induced neovascularization with enhanced engraftment. To elucidate the mechanism underlying these ADSC changes, we compared the surface marker profiles of freshly isolated ADSCs obtained from diabetic and non-diabetic patients by flow cytometry. Among studied subsets, the CD34+CD31-CD271+ subpopulation was reduced in the adipose tissues of diabetic patients. In addition, SOX2 expression and proliferative capacity were considerably reduced in nonDM-ADSCs derived from the stromal vascular fraction (SVF) with depletion of CD271+ cells (p < 0.01). Our observations elucidated that reduced CD271+ subpopulation is critical for the impairment of ADSCs in diabetic patients. Further investigations on the CD271+ subset of ADSCs might provide novel insights into the mechanisms and solutions for diabetes-related ADSC dysfunction in cell therapy. In the part of experimental materials, we found many familiar compounds, such as 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Category: ethers-buliding-blocks)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) is a third-generation synthetic retinoid and a highly lipophilic compound derived from naphthoic acid. It is widely used in the treatment of acne.Category: ethers-buliding-blocks

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Journal of Drug Delivery Science and Technology included an article by Medina, David X.; Chung, Eugene P.; Bowser, Robert; Sirianni, Rachael W.. Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《Lipid and polymer blended polyester nanoparticles loaded with adapalene for activation of retinoid signaling in the CNS following intravenous administration》. The information in the text is summarized as follows:

Small mol. retinoids are potential therapeutics for a variety of neurol. diseases. However, most retinoids are poorly water soluble and difficult to deliver in vivo, which prevents further study of their utility to treat disease. Here, we focus on adapalene, an FDA approved drug that is a specific agonist for the retinoic acid receptor β (RARβ). We sought to develop nanoparticle delivery systems that would enable effective delivery of adapalene to the CNS. We developed strategies to produce nanoparticles based on the hypothesis that incorporation of hydrophobic mols. into a polyester base would improve adapalene loading. In the first scheme, poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) was blended with low mol. weight poly(lactic acid) (PLA) or poly(caprolactone) (PCL). In the second scheme, poly(lactic-co-glycolic acid) (PLGA) was blended with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)] (DSPE-PEG). Our data demonstrate that blending low mol. weight polyesters or DSPE-PEG into the primary nanoparticle base improves encapsulation of adapalene, presumably by enhancing adapalene solubility in the nanoparticle. Peripheral administration of these nanoparticles activated retinoid signaling in the brain and spinal cord of healthy mice. These studies provide new approaches for nanoparticle fabrication and establish proof of principle that systemically administered, adapalene-loaded nanoparticles activate retinoid signaling in the CNS. In the experiment, the researchers used many compounds, for example, 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Application In Synthesis of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2018,Guanziroli, Elena; Venegoni, Luigia; Fanoni, Daniele; Cavicchini, Stefano; Coggi, Antonella; Ferrero, Stefano; Gianotti, Raffaele; Berti, Emilio; Del Gobbo, Alessandro published 《Immunohistochemical expression and prognostic role of CD10, CD271 and Nestin in primary and recurrent cutaneous melanoma.》.Italian journal of dermatology and venereology published the findings.Application of 106685-40-9 The information in the text is summarized as follows:

BACKGROUND: CD10, CD271 and Nestin, which are proteins associated with tumor-initiating properties and/or progression potential, have not been specifically studied on malignant melanoma (MM) with cutaneous recurrences. METHODS: We evaluated the expression of CD10, CD271 and Nestin in 27 tumor samples from 16 patients. These tumor samples corresponded to 6 primary melanomas which developed 11 ITM and 10 primary melanomas without recurrences at 10-year follow-up from specimens obtained from surgical excisions of patients referred to the Unit of Dermatology, Department of Medical-Surgical and Transplant Physiopathology, University of Milan, between 2006 and 2016. RESULTS: We demonstrated a higher expression of CD271 and Nestin in primary tumors which recurred than control population, Nestin was expressed with significantly higher percentages in primary tumors than recurrences, and CD10 expression was statistically significant correlated with disease-free survival: cases with a lower score recurred lately than cases with higher scores. CONCLUSIONS: Our preliminary results suggested that CD271 and Nestin can be considered early biomarkers for the development of ITM, Nesting can be useful in differentiating primary MM from cutaneous recurrences and CD10 is associated with a rapid disease progression and may be considered a potential prognostic marker. In the part of experimental materials, we found many familiar compounds, such as 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Application of 106685-40-9)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Application of 106685-40-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Photodermatology, Photoimmunology & Photomedicine included an article by Nicklas, Claudia; Rubio, Rocio; Cardenas, Consuelo; Hasson, Ariel. Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial》. The information in the text is summarized as follows:

Although progress has been made in the study of photodynamic therapy for acne, studies using current recommended therapies as active comparators are lacking. Randomized, controlled trial involving 46 patients with moderate inflammatory facial acne, 23 patients received two sessions of PDT separated by 2 wk (ALA 20% incubated 1.5 h before red light irradiation with 37 J/cm2 fluence) and 23 patients received doxycycline 100 mg/d plus adapalene gel 0.1%. In both groups, from the sixth week, we started adapalene gel 0.1% as maintenance therapy until 12 wk of follow-up. Primary end point was the reduction of acne lesions at the 6-wk follow-up, which was evaluated by 2 investigators blinded to the intervention. The median percent reductions in noninflammatory lesion count (P = 0.013) and total lesions (P = 0.038) at 6 wk was found to be significantly higher in the group receiving PDT. At 12 wk there was a greater reduction of inflammatory lesions in PDT group with 84% vs. 74% for group who received doxycycline plus adapalene (P = 0.020) as well as in reducing total lesions with 79% vs. 67% resp. (P = 0.026). No severe side-effects were observed for either therapy. ALA-PDT offers promise as an alternative treatment for moderately severe inflammatory acne that has a higher effectiveness than the combination of doxycycline and adapalene gel in reducing noninflammatory and total lesions at 6 wk. There were significantly superior reductions at 12 wk in the combination of PDT group followed by adapalene gel in total, inflammatory, and noninflammatory lesions.6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid) was used in this study.

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

In 2019,Journal of Drug Delivery Science and Technology included an article by Bubic Pajic, Natasa; Ilic, Tanja; Nikolic, Ines; Dobricic, Vladimir; Pantelic, Ivana; Savic, Snezana. Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《Alkyl polyglucoside-based adapalene-loaded microemulsions for targeted dermal delivery: Structure, stability and comparative biopharmaceutical characterization with a conventional dosage form》. The information in the text is summarized as follows:

Aiming to develop biocompatible microemulsions based on natural alkyl polyglucoside surfactant as prospective carriers for improved dermal delivery of adapalene, phase behavior and microstructure of pseudo-ternary oil/decyl glucoside/propylene glycol/water systems were evaluated. The chosen inverted bicontinuous formulations did not change their microstructure upon drug incorporation and remained stable during 1-yr period. Preliminary in vivo assessment of skin performances suggested satisfying safety profiles of placebo microemulsions, in spite of considerable changes in skin hydration and barrier function. Interestingly, despite lower in vitro drug release, the amount of adapalene penetrated into porcine skin under infinite dosing regime was higher from microemulsions than from com. drug product, reaching dermal retention enhancement ratio of 5.9. However, by changing exptl. conditions to the more realistic in-use situation, the amount of adapalene extracted from the stratum corneum was comparable for microemulsions and marketed product. Similarly, the drug deposition in hair follicles was slightly pronounced with novel microemulsion vehicles (183.30 ± 156.32 ng/cm2 and 167.39 ± 108.96 ng/cm2 vs. 157.00 ± 114.91 ng/cm2), highlighting the importance of proper selection of exptl. conditions when assessing trans(dermal) drug delivery. Consequently, our results suggest that alkyl polyglucoside based microemulsions are promising vehicles worth exploring further for targeted intraderdermal delivery of adapalene in acne treatment. In the experiment, the researchers used many compounds, for example, 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid)

6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Quality Control of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem